RxDoctor Payments Data

Ellis Hedaya, MD

Neurology · Atlanta, GANPI 1528032596

Payments from drug & device makers

$7,776in general payments, 2019–2025

Across 352 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biogen$559
  • AstraZeneca$481
  • UCB, Inc.$463
  • EMD Serono, Inc.$459
  • Novartis$423
  • plus $4K from 44 others

What the payments were for

  • Consulting fees$3004%
  • Food & beverage$7,23693%
  • Education$2403%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,776 in reported general payments places this provider in the 70th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$61,653
Medicare patients
249
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rebif RebidoseInterferon Beta-1a/Albumin12$126,143
NuplazidPimavanserin Tartrate15$73,543
Emgality PenGalcanezumab-Gnlm41$39,524
XcopriCenobamate20$25,990
Nurtec OdtRimegepant Sulfate14$23,676
Aimovig AutoinjectorErenumab-Aooe29$22,756
Carbidopa-LevodopaCarbidopa/Levodopa210$8,965
Sumatriptan Succinate38$7,899
Dalfampridine ErDalfampridine12$7,200
Memantine Hcl235$6,312
LinzessLinaclotide12$6,157
Levetiracetam101$5,845
Tegretol XrCarbamazepine13$4,596
Oxcarbazepine54$4,388
Gabapentin170$3,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$184$73,54315 claims
PfizerNurtec Odt, Dilantin$235$27,36432 claims
SK Life Science, Inc.Xcopri$198$25,99020 claims
AbbVieLinzess$1,390$6,15712 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$63$2,04312 claims
Upsher-smith Laboratories LLCTopiramate$22$1,11495 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 506 neurology providers in Georgia.

Other neurology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →